Shanghai Zhangjiang Biotech

Shanghai Zhangjiang Biotech is a Chinese biotechnology company specializing in the research, development, and manufacturing of monoclonal antibody drugs and biosimilars. Founded in 1998 and currently operating as a key subsidiary of Mabpharm Limited, the company is a pioneer in the Chinese biologics industry, headquartered in the Zhangjiang High-tech Park in Shanghai. Its portfolio includes several approved products in China, most notably CMAB008 (an infliximab biosimilar) for autoimmune diseases and CMAB007 (an omalizumab biosimilar) for allergic asthma. The company maintains a robust pipeline of antibody candidates targeting EGFR, RANKL, and PD-1, supported by integrated R&D and large-scale manufacturing capabilities. Shanghai Zhangjiang Biotech is dedicated to providing high-quality, affordable biological therapies to address unmet medical needs in oncology and immunology.